NOVARTIS

Novartis wins European approval for biosimilar version of Roche`s MabThera

Novartis wins European approval for biosimilar version of Roche`s MabThera

Published 19/06/2017

Swiss drugmaker Novartis on Monday said it had won European approval for its biosimilar version of Roche's blockbuster Rituxan as the crosstown rivals go head-to-head on a drug to treat blood cancers and immunological diseases.

[more…]

South Korea to fine Novartis unit over unfair drug promotions

South Korea to fine Novartis unit over unfair drug promotions

Published 08/06/2017

FILE PHOTO: The logo of Swiss drugmaker Novartis AG is seen at its headquarters in Basel, Switzerland, January 25, 2017. REUTERS/Arnd Wiegmann/File Photo

South Korea's antitrust regulator said it would fine Novartis' local unit 500 million won ($444,089) for alleged unfair promotions, in another setback for the Swiss drugmaker that was fined earlier this year over kickbacks to doctors.

[more…]

Novartis says U.S. regulator grants speedy review of CAR-T cell therapy

Novartis says U.S. regulator grants speedy review of CAR-T cell therapy

Published 30/03/2017

FILE PHOTO: The logo of Swiss drugmaker Novartis AG is seen at its headquarters in Basel, Switzerland, January 25, 2017. REUTERS/Arnd Wiegmann/File Photo

Novartis AG on Wednesday said the U.S. Food and Drug Administration (FDA) has agreed to accelerate its review of the Swiss drugmaker's CTL019 therapy for young patients with B-cell acute lymphoblastic leukemia.

[more…]

Novartis wins CHMP nod for drug combo against some lung cancers

Novartis wins CHMP nod for drug combo against some lung cancers

Published 24/02/2017

The logo of Swiss drugmaker Novartis AG is seen at its headquarters in Basel, Switzerland January 25, 2017. REUTERS/Arnd Wiegmann

Swiss drugmaker Novartis's drugs Tafinlar and Mekinist edged closer to approval in Europe to be used together against a type of lung cancer after a key committee on Friday published a recommendation to expand the combination's indications.

[more…]

Novartis cancer drug Zykadia gets FDA priority review

Novartis cancer drug Zykadia gets FDA priority review

Published 23/02/2017

The logo of Swiss drugmaker Novartis AG is seen at its headquarters in Basel, Switzerland January 25, 2017. REUTERS/Arnd Wiegmann

The U.S. Food and Drug Administration (FDA) has granted priority review to Novartis drug Zykadia as a first-line treatment for some lung cancer patients, the Swiss drugmaker said on Thursday.

[more…]

Novartis eye drug franchise takes hit with failed Fovista studies

Novartis eye drug franchise takes hit with failed Fovista studies

Published 12/12/2016

The logo of Swiss drugmaker Novartis is seen at its headquarters in Basel, Switzerland October 22, 2013. REUTERS/Arnd Wiegmann/File Photo

Swiss drugmaker Novartis's bid to bolster its eye drug portfolio suffered a setback on Monday when it announced combining Lucentis with Fovista in patients with neovascular age-related macular degeneration (nAMD) did not produce better outcomes than treatment with Lucentis alone.

[more…]

Novartis says 82 percent of leukemia patients in remission after CAR-T

Novartis says 82 percent of leukemia patients in remission after CAR-T

Published 05/12/2016

A Novartis logo is pictured on its headquarters building in Mumbai April 1, 2013. REUTERS/Vivek Prakash/File Photo

An experimental cancer therapy being developed by Novartis AG eliminated an aggressive form of blood cancer in 82 percent of children and young adults treated with modified immune cells in a mid-stage trial, the company said on Saturday.

[more…]

Novartis backs off from 2016 date for testing Google autofocus lens

Novartis backs off from 2016 date for testing Google autofocus lens

Published 21/11/2016

The Google logo adorns the entrance of Google Germany headquarters in Hamburg, Germany July 11, 2016. Picture taken July 11, 2016. REUTERS/Morris Mac Matzen

Novartis has abandoned a 2016 goal to start testing its autofocus contact lens on people, though it said the groundbreaking product it is making with internet giant Google is "progressing steadily."

[more…]

Novartis chairman says considering sale of Alcon eye care division

Novartis chairman says considering sale of Alcon eye care division

Published 15/11/2016

The logo of Swiss pharmaceutical company Novartis is seen on its headquarters building in Basel, Switzerland October 27, 2015. REUTERS/Arnd Wiegmann

Drugmaker Novartis (NOVN.S) is considering to sell its struggling Alcon eye care division, its chairman said in an interview with Swiss weekly SonntagsZeitung.

[more…]

Novartis leukemia drug wins FDA priority review

Novartis leukemia drug wins FDA priority review

Published 15/11/2016

A Novartis logo is pictured on its headquarters building in Mumbai April 1, 2013. REUTERS/Vivek Prakash/File Photo

Novartis's investigational drug PKC 412 won U.S. Food and Drug Administration priority review, the Swiss drugmaker said on Monday, keeping up momentum after the prospective treatment for a fast-growing form of leukemia garnered breakthrough therapy status this year.

[more…]